申请人:Takeda Pharmaceutical Company Limited
公开号:EP2336105A1
公开(公告)日:2011-06-22
The present invention relates to a compound represented by the formula
wherein ring A is a nitrogen-containing heterocycle;
ring B is an aromatic ring optionally having substituent(s);
ring D is an aromatic ring optionally having substituent(s);
L is a group represented by the formula
R2, R3, R4a and R4b are each independently a hydrogen atom, an optionally halogenated C1-6 alkyl group or an optionally halogenated C3-6 cycloalkyl group, or R2 and R3 are optionally bonded via an alkylene chain or an alkenylene chain, or R4a and R4b are optionally bonded via an alkylene chain or an alkenylene chain;
R1 is a hydrogen atom or a substituent;
m and n are each independently an integer of 0 to 5;
m+n is an integer of 2 to 5; and
- - - is a single bond or double bond, or a salt thereof; and the like. The compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, digestive tract diseases, central neurological disease and the like.
本发明涉及一种由式表示的化合物
其中环 A 是含氮杂环;
环 B 是可选具有取代基的芳香环
环 D 是可选具有取代基的芳香环;
L 是由式
R2、R3、R4a 和 R4b 各自独立地为氢原子、任选卤代的 C1-6 烷基或任选卤代的 C3-6 环烷基,或 R2 和 R3 任选通过亚烷基链或烯链键合,或 R4a 和 R4b 任选通过亚烷基链或烯链键合;
R1 是氢原子或取代基;
m 和 n 各自独立地为 0 至 5 的整数;
m+n 是 2 至 5 的整数;以及
--是单键或双键,或其盐;等等。该化合物具有优异的速激肽受体拮抗作用,可作为预防或治疗各种疾病(如下尿路疾病、消化道疾病、中枢神经疾病等)的药物。